TAXIS Pharmaceuticals
TAXIS Pharmaceuticals is dedicated to addressing the root cause of antimicrobial resistance by developing innovative therapies that target resistant bacteria. Their mission is to create novel solutions to combat drug-resistant infections, particularly focusing on disrupting bacterial mechanisms and developing anti-resistance drugs. They aim to lay the groundwork for future advancements in antibiotic development and to improve patient outcomes in the fight against resistant bacteria.
Industries
Nr. of Employees
small (1-50)
TAXIS Pharmaceuticals
Patents
Products
Oral FtsZ‑targeting clinical candidate (anti‑staphylococcal)
An oral small‑molecule, first‑in‑class candidate that inhibits the bacterial FtsZ cell‑division protein; progressed through Phase I clinical testing with reported tolerability and no serious adverse events, and developed for use in combination strategies to address resistant Staphylococcus aureus infections.
Preclinical efflux pump inhibitor candidates
Small‑molecule efflux pump inhibitors developed to block bacterial efflux mechanisms and potentiate the activity of multiple antibiotic classes; candidates show in vitro and in vivo potentiation and are undergoing lead optimization supported by public grants.
Preclinical DHFR inhibitor program
Preclinical small‑molecule program targeting bacterial dihydrofolate reductase to address highly resistant Neisseria gonorrhoeae strains and other resistant pathogens.
Oral FtsZ‑targeting clinical candidate (anti‑staphylococcal)
An oral small‑molecule, first‑in‑class candidate that inhibits the bacterial FtsZ cell‑division protein; progressed through Phase I clinical testing with reported tolerability and no serious adverse events, and developed for use in combination strategies to address resistant Staphylococcus aureus infections.
Preclinical efflux pump inhibitor candidates
Small‑molecule efflux pump inhibitors developed to block bacterial efflux mechanisms and potentiate the activity of multiple antibiotic classes; candidates show in vitro and in vivo potentiation and are undergoing lead optimization supported by public grants.
Preclinical DHFR inhibitor program
Preclinical small‑molecule program targeting bacterial dihydrofolate reductase to address highly resistant Neisseria gonorrhoeae strains and other resistant pathogens.
Services
End‑to‑end discovery and preclinical development services for small‑molecule antibacterial programs, including target‑based screening, medicinal chemistry, microbiology and susceptibility testing, in vivo efficacy studies, and IND‑enabling study planning.
Advisory services for regulatory strategy and preparation of IND‑enabling programs for infectious disease candidates, including alignment of nonclinical packages with regulatory expectations and navigation of applicable incentive pathways.
Consulting and joint research collaborations providing expertise in medicinal chemistry, microbiology, pharmacology, ADME/PK and toxicology to support project progression and grant applications.
End‑to‑end discovery and preclinical development services for small‑molecule antibacterial programs, including target‑based screening, medicinal chemistry, microbiology and susceptibility testing, in vivo efficacy studies, and IND‑enabling study planning.
Advisory services for regulatory strategy and preparation of IND‑enabling programs for infectious disease candidates, including alignment of nonclinical packages with regulatory expectations and navigation of applicable incentive pathways.
Consulting and joint research collaborations providing expertise in medicinal chemistry, microbiology, pharmacology, ADME/PK and toxicology to support project progression and grant applications.
Expertise Areas
- Antibacterial small‑molecule discovery
- Medicinal chemistry and SAR optimization
- Preclinical microbiology and in vivo infection models
- ADME/PK and PK/PD modeling
Key Technologies
- FtsZ‑targeting small‑molecule inhibitors (first‑in‑class)
- Efflux pump inhibition platforms for antibiotic potentiation
- Dihydrofolate reductase (DHFR) inhibition
- Medicinal chemistry and structure‑activity relationship (SAR) methods
News & Updates
Development of TXA709, the First Product Targeting FtsZ Proteins
TXA709 is a groundbreaking product targeting bacterial cell division protein FtsZ, marking a significant advancement in anti-resistance therapies.
Development of TXA709, the First Product Targeting FtsZ Proteins
TXA709 is a groundbreaking product targeting bacterial cell division protein FtsZ, marking a significant advancement in anti-resistance therapies.